National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
Center for Biomedical Imaging, Department of Radiology, New York University School of Medicine, NY, New York, USA.
Commun Biol. 2023 Feb 10;6(1):166. doi: 10.1038/s42003-023-04545-3.
Dopamine facilitates cognition and is implicated in reward processing. Methylphenidate, a dopamine transporter blocker widely used to treat attention-deficit/hyperactivity disorder, can have rewarding and addictive effects if injected. Since methylphenidate's brain uptake is much faster after intravenous than oral intake, we hypothesize that the speed of dopamine increases in the striatum in addition to its amplitude underly drug reward. To test this we use simulations and PET data of [C]raclopride's binding displacement with oral and intravenous methylphenidate challenges in 20 healthy controls. Simulations suggest that the time-varying difference in standardized uptake value ratios for [C]raclopride between placebo and methylphenidate conditions is a proxy for the time-varying dopamine increases induced by methylphenidate. Here we show that the dopamine increase induced by intravenous methylphenidate (0.25 mg/kg) in the striatum is significantly faster than that by oral methylphenidate (60 mg), and its time-to-peak is strongly associated with the intensity of the self-report of "high". We show for the first time that the "high" is associated with the fast dopamine increases induced by methylphenidate.
多巴胺有助于认知,并与奖励处理有关。哌醋甲酯是一种广泛用于治疗注意力缺陷多动障碍的多巴胺转运体阻滞剂,如果注射,可能会产生奖励和成瘾作用。由于静脉内摄入比口服摄入后哌醋甲酯在大脑中的摄取速度快得多,我们假设多巴胺在纹状体中的增加速度以及其幅度除了在药物奖励之外还有其他基础。为了验证这一点,我们使用了 20 名健康对照者的 [C]raclopride 结合的模拟和 PET 数据,以评估口服和静脉内哌醋甲酯挑战。模拟表明,[C]raclopride 在安慰剂和哌醋甲酯条件下的标准化摄取值比率的时变差异是哌醋甲酯诱导的时变多巴胺增加的替代物。在这里,我们表明,静脉内哌醋甲酯(0.25mg/kg)引起的纹状体中多巴胺的增加明显快于口服哌醋甲酯(60mg),并且其峰值时间与自我报告的“高”强度强烈相关。我们首次表明,“高”与哌醋甲酯引起的快速多巴胺增加有关。